All articles tagged with #pmos
Draft NICE guidance would screen up to 4 million UK women with irregular periods for PMOS, using hormone tests and ultrasounds, with annual symptom reviews; IVF would be offered to eligible PMOS patients, while laser hair removal is not funded due to cost‑effectiveness. Consultation runs to 11 August 2026, with final guidelines due December 2026.
A Harvard-led study of about 325 mother–daughter pairs from Project Viva found that higher PFAS levels in mothers during pregnancy were associated with daughters who later developed PMOS (the renamed PCOS) and acne, with about 2.3–2.7× higher odds. Specific chemicals such as N-EtFOSAA and PFNA were linked to PMOS and acne. While the findings add to evidence of PFAS as endocrine disruptors, the study’s small, mostly white, highly educated sample means more research is needed. Practical tips include avoiding stain guards and other high-PFAS textiles and choosing organic, home-cooked meals to reduce exposure.
Briony May Williams, a 2018 Great British Bake Off contestant who later became a TV presenter, credits her 2013 diagnosis of polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS) with sparking her baking journey and on-screen career; she manages PMOS with medication and diet and hopes the name change raises awareness and speeds diagnosis for other women.
The International PCOS Network renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its metabolic and endocrine nature and improve understanding, diagnosis, and treatment; proponents hope the change will help more women receive faster referrals and appropriate care, though experts say a name change alone won't cure the condition, which still requires symptom management.
Experts rename polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS) to reflect its broader hormonal and metabolic features, not just ovarian cysts; diagnosis centers on irregular periods and signs of high androgens, with infertility and pregnancy risks acknowledged. Treatment emphasizes lifestyle changes and individualized options such as metformin, anti-androgens, and hormonal birth control based on fertility goals.
PMOS, the official rename of PCOS (polycystic ovarian syndrome), reframes the condition as a multisystem endocrine and metabolic disorder driven largely by insulin resistance, not just ovarian cysts. The Lancet consensus (May 12, 2026) involved about 22,000 experts and 56 organizations to improve diagnosis, reduce stigma, and guide treatment toward metabolic health and personalized care. Diagnosis now emphasizes signs of androgen excess, menstrual history, and metabolic testing, with management focusing on lifestyle changes, glucose control, and targeted therapies, while fertility considerations are addressed when relevant. It is lifelong but manageable with proper care and advocacy.
Victoria Song argues that renaming PCOS to PMOS reflects a broader hormonal and metabolic condition, and that personalized health tech is not yet capable of reliably addressing chronic illnesses. While wearables and AI promise tailored guidance, PMOS manifests differently across individuals, interacts with insulin resistance and medications, and is influenced by factors like hormonal contraception, making universal personalization elusive. Despite industry optimism, real-world personalization still requires significant self-tracking, medical input, and trial-and-error, highlighting a gap between hype and what current science and healthcare systems can safely deliver.
After a 14-year global consensus involving 56 organizations and about 22,000 participants, Polycystic Ovary Syndrome is officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to reflect its systemic hormonal and metabolic nature. The rename aims to reduce stigma, improve diagnosis, and align clinical practice over the next three years, with around 1 in 8 women affected by PMOS. The effort was led by researchers including Prof. Helena Teede and advocacy by Lorna Berry, highlighting the shift away from a cyst-centric view to a broader endocrine health perspective.
Global experts have renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its multisystem effects. The change, backed by 56 organizations after more than a decade of consultation and published in The Lancet, aims to reduce diagnostic delays and misperceptions by emphasizing endocrine and metabolic factors over ovarian cysts, potentially guiding future research toward metabolic roots like insulin resistance and chronic inflammation and reshaping how the condition is diagnosed and treated.
PMOS—polyendocrine metabolic ovarian syndrome—replaces PCOS to better reflect its metabolic and endocrine nature and reduce misdiagnosis; the rename, published in The Lancet after 14 years of work, aims to improve care. PMOS features irregular periods and excess androgens, can cause acne or hair changes, and is linked to infertility and metabolic risks; treatment focuses on lifestyle changes (diet, exercise, sleep) and personalized options like Metformin, anti-androgens, or hormonal birth control. The change seeks to raise awareness and better tailor care for patients.
A global health consortium renames polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better capture its multisystem nature, remove the misleading focus on ovaries, and reduce stigma. After 14 years of collaboration, the group plans to push PMOS into ICD classifications within three years and raise public and professional awareness. The condition affects about 170 million people worldwide, with up to 70% undiagnosed, and often involves metabolic, endocrine, psychological, and dermatological symptoms beyond reproduction. The renaming emphasizes insulin resistance and diabetes risk, potentially guiding research, screening, and treatment, including the continued, and sometimes off-label, use of drugs like metformin. The Lancet policy paper outlines the strategy to educate globally and secure official ICD updates.
Global experts publish in The Lancet a multiyear, multistakeholder process renaming polycystic ovary syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to avoid the cyst misnomer and better reflect its hormonal and metabolic features, with an eight‑stage plan—from dissemination and resource development to health‑system integration, policy alignment, and international guideline updates—aimed at clearer diagnosis and improved care.
Health researchers have renamed PCOS to PMOS (polyendocrine metabolic ovarian syndrome) to better reflect its wide hormonal and metabolic effects; a global consortium says the old name contributed to delayed diagnosis, stigma, and siloed research. The change could alter clinical care by prompting broader metabolic and cardiovascular screening, expand funding beyond reproductive health, and spur new treatments for the roughly 10–13% of reproductive-age women affected.
A Lancet-published renaming led by endocrinologist Helena Teede changes polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to reflect the disorder’s wide metabolic and cardiovascular effects. Diagnosis shifts away from ovarian cysts, using 2 of 3 criteria (androgens, irregular menses, or high AMH/ovarian follicles), with ultrasound needing less emphasis. The rename is intended to broaden research funding and change treatment approaches beyond fertility, with PMOS slated to replace PCOS in ICD classification by 2028, though some opposition from those tied to the PCOS branding is expected.
Medical experts say PCOS should be renamed polyendocrine metabolic ovarian syndrome (PMOS) to capture its wide-ranging effects on metabolic, endocrine, cardiovascular, reproductive, and mental health, with the aim of improving diagnosis, treatment, and research.